Full Press Release Details
HONG KONG--(BUSINESS WIRE)--Zoar Limited (NYSE American: ZOAR) (“Zoar” or the “Company”), a global pharmaceutical company focused on the development and manufacturing of complex active pharmaceutical ingredients (“APIs”) and intermediates, today announced that it has completed its business combination involving the Company, Impact Biomedical Inc. (“Impact”), Dr Ashleys Nevada Sub Inc. and Zoar Labs Limited (“Zoar Labs”) (the “Business Combination”). Zoar’s ordinary shares are expected to begin